We are composed of Sumitomo Pharma (Suzhou) Co., Ltd. and Sumitomo Pharma (China) Co., Ltd.and Sumitomo Pharma Trading (Suzhou) Co., Ltd. Since its entry into the Chinese market in the 1990s, Sumitomo Pharma (Suzhou) Co., Ltd.has been making efforts to bring China into one of the dominant pharmaceutical marketing operation bases. By adopting global advanced production technologies in China, Sumitomo Pharma (Suzhou) Co., Ltd. provides patients with high-quality pharmaceutical products and therapeutic solutions in the areas of the central nervous system, infection prevention, cardiovascular diseases, and gastrointestinal tract disorders. A huge number of patients have benefited over the years. Meanwhile, the Company actively participates in a variety of social welfare undertakings and fully supports the comprehensive development of China's healthcare sector.
The Company's medication Almarl® entered the Chinese pharmaceutical market in 1995. Later in 2000, Sumitomo Pharma Shanghai Office was established. In 2003, Sumitomo Pharma (Suzhou) Co., Ltd contributed by Sumitomo Pharma Co., Ltd., was established as a wholly-owned subsidiary in China. Sumitomo Pharma (Suzhou) Co., Ltd.has a large production base in Suzhou City that comprises a manufacturing plant and a packaging factory. To facilitate data collection, market research, and product promotion locally, it also opened branches in Beijing, Shanghai, and Guangzhou cities. After merging with Sumitomo Pharma (Suzhou) Co., Ltd. (Shanghai) International Trading Co., Ltd. in 2008, Sumitomo Pharma (Suzhou) Co., Ltd.has nearly 600 employees in China, became a pharmaceutical company integrating Research & Development (R&D), production, and sale. Presently, Sumitomo Pharma (Suzhou) Co., Ltd. has built a nationwide marketing network and improved its R&D system. Sales in 2021 have fetched RMB 2 billion.
Sumitomo Pharma (Suzhou) Co., Ltd. is actively involved in the scientific exploration of neuropsychiatric diseases and infections. Many advanced pharmaceutical products have been researched and developed, several of which became indispensable in clinical medication for saving countless lives. In the future, Sumitomo Pharma (Suzhou) Co., Ltd. will work with the parent company to conduct concurrent clinical trials so that more new drugs can be developed for patients in China as soon as possible.
Sumitomo Pharma(Suzhou)Co.,Ltd. always adheres to the concept of "Patient First" and continues to deepen ploughing the Chinese market, aiming to become a Global Specialized Player, striving to make more contributions to the long-term development of healthcare industry in China.
We value above all the health of the patients we serve today and in the future
We always approach our work with uncompromising sincerity, honesty and dignity
We respect each other's individuality and value our combined strength as “One Team” with diversity
Follow through on our Slogan "Innovation today, healthier tomorrows."
We constantly pursue self-innovation to deliver innovative products and services with speed so that people around the world can lead healthier and more fulfilling lives.
Pursue trustworthy corporate activities.
We comply with laws and regulations, and conduct transparent and fair corporate activities with the highest level of ethics.
We resolutely sever all relations with antisocial forces and organizations that present a threat to the order and security of civil society.
Transparently disclose and properly manage information.
We disclose corporate information in a timely and appropriate manner.
We take appropriate measures to protect and manage personal and customer information acquired through corporate activities.
Improve individual capabilities and collaborate with peers.
We work together with respect for diversity, character and personality of peers in an effort to create a healthy and safe work environment.
We focus on doing our best work as we strive for results in an organization that provides opportunities to grow and develop new skills.
Positively address global environmental issues.
We engage in all aspects of our corporate activities in consideration of the environment.
Build harmonious relationships with society.
We value communications with all of our stakeholders and promote initiatives contributing to the realization of a sustainable society.
We consider the local culture and customs of the countries and regions in which we operate, and contribute toward local economic and social development of those communities.
努力实现“Innovation today,healthier tomorrows”
为了人们更健康、自在的生活，时刻要求自己做出新的变革，不断挑战、迅速实现创新。
遵守法律法规、秉持高度的诚信和伦理观，进行公正的企业活动（Compliance)
坚持业界更高水平的合规体制并不断完善，开展正直诚信的企业活动，以维护和提高来自社会的信赖。
践行以患者为中心的活动（Contribution)
通过开展受社会及相关各方认可的企业活动，实现业务的持续发展和对医疗事业的持续贡献。人人主动开展行动，履行各自的责任和使命。
追求与内外部相关各方的协调与合作（Communication)
重视与相关各方的对话，推动社会贡献。行动时充分考虑地球环境问题，通过企业活动助力区域社会的发展。推进公司内部更紧密的合作，
促进与医疗相关人员恰当地开展高质量的沟通。
时常树立高远目标，为实现目标不懈努力（Challenge）
不断提高企业活动的质量、为社会和医疗事业做出贡献，持续向高标准发起挑战。
充分发挥员工的能力，支持每一位员工的进一步成长
尊重员工的多样性、人格、个性，打造员工间互相尊重・尊敬、共同成长的公司。追求安全、良好的职场环境和最合适的工作方式，并提供员工能力发展的机会。
Hello, everyone! I am Yoshitaka Koketsu, the Chairman and CEO of Sumitomo Pharma Group in China.
As one of the important members of the Sumitomo Group, Sumitomo Pharma Co., Ltd. has inherited the corporate spirit from the 400-year-old Sumitomo Group. It entered the Chinese market in the 1990s and incorporated Sumitomo Pharma (Suzhou) Co., Ltd. (hereinafter referred to as "Sumitomo Pharma") in December 2003. Sumitomo Pharma has put over nearly 20 years of strenuous efforts, and it has always regarded China as a key strategic marketing platform. In order to accomplish this, it has been implementing advanced production technologies in China and cooperating with ecosystem partners to continuously provide high-quality medicines for Chinese patients and promote the development of high-quality China's medical industry.
Sumitomo Pharma is a company that keeps forging ahead with determination and challenging itself to create new value for patients and help people achieve more health and happiness. As a global pharmaceutical company, we have cutting-edge R&D technologies, a stable production capacity, and a high-quality sales team. We shape the development with innovation, apply the concept of patient-oriented management throughout every process of the company's operations, and strive for the health of human beings in the ever-changing market environment.
As a corporate citizen in Chinese society, we actively fulfill our corporate social responsibilities, give full play to our expertise in the medical and health fields and empower the sustainable development in Chinese society. In the future, we will continue to consolidate our foundation of corporate operations, strictly abide by Chinese laws and regulations, and strengthen enterprise risk management and control.
With this, I would like to sincerely thank you for your attention and support of Sumitomo Pharma. We will rise to challenges, pursue excellence, and continuously create and contribute new value to human health and happiness in the future.
Thank you very much.
Yoshitaka Koketsu
Chairman and CEO
Sumitomo Pharma (China) Co., Ltd. (“Regional Headquarters”) was established in Huangpu District of Shanghai on June 28, 2022 and was approved as the regional headquarters of multinational corporation in October of the same year. Sumitomo Pharma Co., Ltd., the parent company and actual controller, is a world-renowned pharmaceutical corporation and the one and only R&D pharmaceutical company affiliated with Sumitomo Group which has more than 400 years of history.
Based on the Company’s mid-term plan for business development published by Sumitomo Pharma Group in 2022, Sumitomo Pharma (China) Co., Ltd. will further increase its investments in China and introduce more global concurrent development projects of innovative drugs into China with the goal of becoming a Global Specialized Player in 2033. The Regional Headquarters is assigned by the Group to be the management center of China where the whole industry links of drug R&D, manufacturing and commercialization in China are coordinated so as to promote the clinical studies of innovative drugs as well as to accelerate the marketing of new drugs in China.
In addition, Sumitomo Pharma (China) Co., Ltd. will actively respond to China’s market access and foreign investment policies and build up close cooperation with the government, research institutions, clinicians and other stakeholders and business partners to promote the integrated development in China. Sumitomo Pharma (China) Co., Ltd. is going to embrace the opportunity of innovation and increase its investments in the Chinese market, and in this case, to work with more local partners from China and advance the innovation of R&D and business cooperation modes. Sumitomo Pharma will also adhere to the value of “Patient First” and actively fulfill corporate social responsibility to safeguard the health of Chinese patients with innovative medical care and assist China in sustainable development and achieving the strategic goal of “Healthy China 2030”.
Suzhou Plant is the production base of Sumitomo Pharma in China. Covering a land area of approximately 30,000 square meters and a floor area of approximately 9,000 square meters, the plant is not only staffed with knowledgeable management personnel and skilled technicians but also armed with advanced production equipment and testing instruments. The plant is mainly responsible for sub-packaging the patented drugs imported from the parent company in Japan and organizes the production in strict accordance with the GMP principles. It always strives for product quality as the life of the company and attaches great importance to environmental protection and energy conservation.
You are about to leave the official website of Sumitomo Pharma (Suzhou) Co., Ltd. and be redirected to a third-party website. Please be aware of the risks involved.